The fifth element of Russian pharma

 “It is the fifth SPIC in the Russian pharmaceutical industry – thus we are developing competences in a large number of therapeutic areas”, noted Denis Manturov, Minister of the Ministry of Industry and Trade of the Russian Federation, ”It is planned to localize unique drug products which do not have analogues and this makes the Russian Federation actually the second world manufacturing site”. According to the head of the MIT Russia, the facility will manufacture socially significant drug products demanded by the Russian hospitals. These are injectable drugs for treatment of oncological diseases including children, drug products for general anesthesia, blood stopping drugs, drugs for inflammatory diseases treatment as well as severe bacterial and fungal infections.   

“SPIC with NovaMedica is the second one in the Kaluga pharmaceutical cluster. It is obvious for us that this instrument is an effective measure to support investors in implementation of promising projects, confirms responsible attitude of the government of the region to business partners and strengthens our mutually advantageous cooperation. It is important that eventually it will make a favorable impact on localization of innovations in our region, will increase manufacturing volumes of products in demand, tax liabilities as well as will help to create new, including high-tech, working places”, said Anatoly Artamonov, Governor of the Kaluga region. 

“Our portfolio company NovaMedica not only distributes drug products of foreign manufacturers, but also invests into creation of innovations having constructed and launched its own R&D Center in Moscow. The next logical step is to create a local state-of-the-art manufacturing facility which will manufacture both own developed products and drugs from Pfizer portfolio which is the partner of NovaMedica. It is important that 20% of all the biotech products manufactured at the facility will be exported as it is envisaged by the SPIC conditions,” said Anatoly Chubais, Chairman of the Executive Board of Managing Company “RUSNANO” and Chairman of the Board of Directors of NovaMedica.

“The Government of Russia creates powerful instruments to enhance transfer of foreign pharmaceutical technologies to Russia. With the help based on large experience, knowledge and investments of our investors and Pfizer, our strategic partner, as well as on the opportunities provided to us by the state, we are creating a plant which will set new high standards of localization of foreign pharmaceutical innovations in Russia,” said Alexander Kuzin, General Director of NovaMedica.